Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?
Gemma Conte, Gabriella Costabile, Domizia Baldassi, Valeria Rondelli, Rosaria Bassi, Diego Colombo, Giulia Linardos, Ersilia Fiscarelli, Raffaella Sorrentino, Agnese Miro, Fabiana Quaglia, Paola Brocca, Ivana d’Angelo, Olivia M. Merkel, Francesca Ungaro
Abstract
NFκB gene silencing was achieved in LPS-stimulated 16HBE14o- cells. Overall, the results highlight the potential of non-PEGylated hNPs as carriers for pulmonary delivery of siRNA for local treatment of CF lung disease. Furthermore, this study provides a detailed understanding of how distinct models may provide different information on nanoparticle interaction with the mucus barrier.
Topics & Concepts
PEGylationMucusNanocarriersCystic fibrosisMucociliary clearanceMaterials scienceBiophysicsMucinDrug deliveryNanotechnologyBiologyLungPolyethylene glycolBiochemistryMedicineEcologyGeneticsInternal medicineRNA Interference and Gene DeliveryCystic Fibrosis Research AdvancesNeonatal Respiratory Health Research